Toxicokinetics studies.. (toxicokinetics evaluation in preclinical studies)
sonalinghatmal
398 views
16 slides
Apr 30, 2024
Slide 1 of 16
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
About This Presentation
Toxicokinetics studies.... Toxicokinetics evaluation in preclinical studies .
m pharm pharmacology. 2 semester.. pharmacological and toxicological screening method 2
Size: 1.89 MB
Language: en
Added: Apr 30, 2024
Slides: 16 pages
Slide Content
Toxicokinetics
Submitted to : Prof.Vaishnavima’am. Submitted by: jamdadesonalilala
Pharmacology department M pharm 1
st
pharmacology
SudhakarRao NaikInstitute Of Pharmacy Pusad
Content
Introduction
Process are involved in toxicokinetics
General principle to be considered
Toxicokineticstudies in preclinical stages.
Toxicokineticstudies in clinical phases .
Introduction
toxicokineticsdescribe the rate of a chemical enter the body and how
the compound metabolise and excrete once it is in the Body.
Toxicokineticsdeals with absorption, distribution biotransformation and
excretion of chemical.
Toxicokineticdefined by the ICH as the generation of pharmacokinetic data
,either as an integral component in conduct of non clinical toxicity studies
or in specially defined supportive studies , to assess systemic exposure.
While developing a molecule as a therapeutic agent researchers consider
not only benefit but also risk associated with it .
Hence toxicological evaluation got more important in drug development
stages especially in pre clinical stages.
•Absorption
absorptionIs the process by which the chemical enters the
body. It depends on the route of administration .
Oral route: the GIT Is most important rote of absorption, as
most acute poisonings involve ingestions.
Dermal rout: lipid solubility of a substance is an important
Factor affecting the degree of absorption through the skin.
Inhalational route: toxic fumes, particulate and noxious gases
may be absorbed through the lungs.
General principles to be considered
1. Quantification of exposure.
2.setting of dose levels
low dose levels
Intermediate dose levels.
High dose levels
3.extent of exposure assessment in toxicity
studies.
4. complicating factors in exposure
interpretation
5. Route of administration.
7. statistical evaluation of data
8. Analytical methods
9. Reporting
Toxicokineticsstudies in preclinical stage:
1.saftey assessment
2. Single dose and rising dose studies repeated Dose toxicity studies
3. repeated dose toxicity studies
4. Genotoxicitystudies.
5. Reproduction toxicity studies.
Studies of fertility
In pregnant and lactating animal.
6. carcinogenicity studies.
Toxicokineticstudies in Clinical Phases:
approaches to decrease the animal usage in toxicokinetics
dried blood spot technology.
Alternative approaches to animal models.
Physiologically based pharmacokinetic modelling.